<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate">
    <meta http-equiv="Pragma" content="no-cache">
    <meta http-equiv="Expires" content="0">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Overview - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1765115033437">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="logo">CRLM LT Resource</div>
            <button class="hamburger" id="hamburger" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <ul class="nav-menu" id="navMenu">
                <li><a href="../index.html">Home</a></li>
                <li><a href="overview.html" class="active">Overview</a></li>
                <li><a href="selection-criteria.html">Selection Criteria</a></li>
                <li><a href="outcomes.html">Clinical Outcomes</a></li>
                <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                <li><a href="survival-curves.html">Survival Curves</a></li>
                <li><a href="pdf-resources.html">PDF Resources</a></li>
                <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                <li><a href="resources.html">Resources</a></li>
                <li><a href="about-research-group.html">About Research Group</a></li>
            </ul>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="content">
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">Home</a> / Overview
            </div>

            <h1>Overview: The Re-emergence of LT for CRLM</h1>

            <section class="section">
                <h2>The Clinical Problem</h2>
                <p>Colorectal cancer (CRC) is a highly prevalent malignancy, with approximately 50% of patients developing liver metastases (CRLM) during the course of their disease. While surgical resection offers the only chance of cure, only 20-30% of patients present with technically resectable disease.</p>
                <p>For the remaining 70-80% with permanently unresectable, liver-confined CRLM, the prognosis is poor:</p>
                <ul>
                    <li><strong>Palliative chemotherapy:</strong> Median OS 24-30 months, 5-year OS &lt;15%</li>
                    <li><strong>Limited treatment options:</strong> Disease progression despite modern systemic therapy</li>
                    <li><strong>Need for curative approaches:</strong> Patients have no alternative to palliative care</li>
                </ul>
            </section>

            <section class="section">
                <h2>Historical Context: Why LT Was Abandoned</h2>
                <p>Liver transplantation for CRLM was explored in the 1980s and 1990s but was largely abandoned due to:</p>
                <div class="info-box">
                    <ul>
                        <li>Poor long-term survival (5-year OS &lt;20%)</li>
                        <li>Limited efficacy of chemotherapy at that time (fluorouracil only, ~20% response rate)</li>
                        <li>Ethical concerns about using scarce donor organs for metastatic disease</li>
                        <li>High rates of early recurrence and mortality unrelated to tumor progression</li>
                    </ul>
                </div>
            </section>

            <section class="section">
                <h2>The Modern Era: Three Key Advances</h2>
                <div class="three-column">
                    <div class="column">
                        <h3>1. Modern Chemotherapy</h3>
                        <p>Doublet and triplet regimens with targeted therapies (anti-EGFR, anti-VEGF) now achieve 54-80% response rates, enabling better disease control before transplant.</p>
                    </div>
                    <div class="column">
                        <h3>2. Improved Immunosuppression</h3>
                        <p>Tailored regimens using tacrolimus, mycophenolate, and everolimus reduce rejection while maintaining anti-tumor immunity.</p>
                    </div>
                    <div class="column">
                        <h3>3. Better Patient Selection</h3>
                        <p>Understanding of tumor biology and development of prognostic scoring systems (Oslo Score, FCRS, PET-MTV) enable identification of patients with favorable disease.</p>
                    </div>
                </div>
            </section>

            <section class="section">
                <h2>The Oslo Experience: Paradigm Shift</h2>
                <p>In 2006, the University of Oslo initiated the SECA-I (Secondary Cancer I) trial, which fundamentally changed the field:</p>
                
                <div class="trial-summary">
                    <h3>SECA-I Trial (2013)</h3>
                    <table class="data-table">
                        <tr>
                            <th>Parameter</th>
                            <th>Value</th>
                        </tr>
                        <tr>
                            <td>Number of Patients</td>
                            <td>21</td>
                        </tr>
                        <tr>
                            <td>5-Year Overall Survival</td>
                            <td>60%</td>
                        </tr>
                        <tr>
                            <td>1-Year Disease-Free Survival</td>
                            <td>35%</td>
                        </tr>
                        <tr>
                            <td>Recurrence Rate</td>
                            <td>90%</td>
                        </tr>
                        <tr>
                            <td>Median Time to Recurrence</td>
                            <td>6 months</td>
                        </tr>
                    </table>
                </div>

                <p><strong>Key Insight:</strong> Despite nearly universal recurrence, overall survival was excellent, suggesting that total hepatectomy removes the primary tumor burden while residual disease exhibits an indolent pattern.</p>
            </section>

            <section class="section">
                <h2>SECA-II: Improved Selection Yields Better Outcomes</h2>
                <p>Building on SECA-I, the SECA-II trial applied stricter selection criteria and achieved even more impressive results:</p>
                
                <div class="highlight-box">
                    <h3>SECA-II Results</h3>
                    <ul>
                        <li><strong>5-Year Overall Survival:</strong> Up to 83% in selected cohorts</li>
                        <li><strong>10-Year Overall Survival:</strong> 88.9% (Oslo Score 0-1)</li>
                        <li><strong>3-Year Disease-Free Survival:</strong> 35%</li>
                        <li><strong>4-Year Survival After Relapse:</strong> 73%</li>
                    </ul>
                </div>

                <p>This demonstrates that LT outcomes in highly selected CRLM patients can be comparable to those for traditional indications like HCC within Milan criteria.</p>
            </section>

            <section class="section">
                <h2>The TransMet Trial: First RCT Evidence</h2>
                <p>The TransMet trial (2024) is the first multicenter, randomized controlled trial comparing LT plus chemotherapy to chemotherapy alone:</p>

                <div class="comparison-table">
                    <table class="data-table">
                        <tr>
                            <th>Outcome</th>
                            <th>LT + Chemotherapy</th>
                            <th>Chemotherapy Alone</th>
                            <th>P-value</th>
                        </tr>
                        <tr>
                            <td><strong>5-Year OS (ITT)</strong></td>
                            <td>56.6%</td>
                            <td>12.6%</td>
                            <td>0.0003</td>
                        </tr>
                        <tr>
                            <td><strong>5-Year OS (Per-Protocol)</strong></td>
                            <td>73.3%</td>
                            <td>9.3%</td>
                            <td>&lt;0.001</td>
                        </tr>
                        <tr>
                            <td><strong>Hazard Ratio</strong></td>
                            <td colspan="2">0.37 (95% CI 0.21-0.65)</td>
                            <td>â€”</td>
                        </tr>
                    </table>
                </div>

                <p><strong>Interpretation:</strong> LT plus chemotherapy reduces the risk of death by 63% compared to chemotherapy alone, providing the highest level of evidence for LT as a new standard option.</p>
            </section>

            <section class="section">
                <h2>Current Status: Transplant Oncology Established</h2>
                <p>LT for CRLM has now transitioned from an experimental concept to a validated clinical practice:</p>
                <ul>
                    <li><strong>International Consensus:</strong> IHPBA published comprehensive guidelines in 2021</li>
                    <li><strong>Growing Adoption:</strong> Increasing number of centers worldwide performing LT for CRLM</li>
                    <li><strong>Multiple Strategies:</strong> Deceased donor LT, living donor LT (LDLT), and innovative surgical techniques (RAPID)</li>
                    <li><strong>Ongoing Trials:</strong> 13+ prospective studies investigating optimal patient selection and treatment sequencing</li>
                </ul>
            </section>

            <section class="section call-to-action">
                <h2>Next Steps</h2>
                <p>To determine if a patient is a candidate for LT, review the <a href="selection-criteria.html">Selection Criteria</a> page, which outlines the Oslo Score, FCRS, PET-MTV, and molecular prognostic factors.</p>
            </section>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1765115033437"></script>
    <script>
        // Hamburger menu toggle
        const hamburger = document.getElementById("hamburger");
        const navMenu = document.getElementById("navMenu");
        
        if (hamburger && navMenu) {
            hamburger.addEventListener("click", function() {
                navMenu.classList.toggle("active");
                hamburger.classList.toggle("active");
            });
            
            // Close menu when a link is clicked
            const navLinks = navMenu.querySelectorAll("a");
            navLinks.forEach(link => {
                link.addEventListener("click", function() {
                    navMenu.classList.remove("active");
                    hamburger.classList.remove("active");
                });
            });
        }
    </script>
    <script>
    </script>
</body>
</html>
